Remarks on the Hormonal Background of the Male Equivalent of Polycystic Ovary Syndrome
Language English Country Czech Republic Media print
Document type Journal Article, Review
Grant support
00023761
Ministerstvo Zdravotnictví Ceské Republiky
PubMed
34137683
DOI
10.14712/23362936.2021.8
PII: pmr_2021122020073
Knihovny.cz E-resources
- Keywords
- Androgens, Insulin resistance, Polycystic ovarian syndrome, Premature androgenic alopecia, SHBG,
- MeSH
- Alopecia etiology MeSH
- Androgens MeSH
- Insulin Resistance * MeSH
- Humans MeSH
- Polycystic Ovary Syndrome * MeSH
- Testosterone MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Androgens MeSH
- Testosterone MeSH
The hypothesis that the most common female endocrine disease, the polycystic ovarian syndrome (PCOS), has a male equivalent, has recently become more widely accepted. The male form of PCOS is marked by alterations in the secretion of gonadotropins, increased insulin resistance, and changes of the levels of several steroid hormones, with clinical manifestations including premature androgenic alopecia (AGA). Because these symptoms are not always found in men with genetic predispositions, knowledge of the male equivalent of PCOS needs to be supplemented by measurements of adrenal 11-oxygenated C19 steroids, particularly 11-keto-, and 11β-hydroxy-derivatives of testosterone and dihydrotestosterone, by focusing on the newly-realized role of skin as an endocrine organ, and by confirming any age-related factors in glucose metabolism disorders in such predisposed men.
References provided by Crossref.org